Evidence map›Paper›PMID 42786170›Full record

ArticleNature communications2026

Methylation Mesa define functional regulatory elements for targeted gene activation.

Y V Liu, J Suryatenggara, H Wong, M K Jayasinghe, J P Tang, H K Tan, J Kwon, Q Zhou, J Zhang, S Moein and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Y V LiuCancer Science Institute of Singapore, Singapore, Singapore.ORCID http://orcid.org/0000-0002-7977-0491
J SuryatenggaraCancer Science Institute of Singapore, Singapore, Singapore.
H WongCancer Science Institute of Singapore, Singapore, Singapore.
M K JayasingheDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
J P TangCancer Science Institute of Singapore, Singapore, Singapore.
H K TanCancer Science Institute of Singapore, Singapore, Singapore.ORCID http://orcid.org/0000-0002-3653-9740
J KwonCancer Science Institute of Singapore, Singapore, Singapore.
Q ZhouCancer Science Institute of Singapore, Singapore, Singapore.
J ZhangHarvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA.
S MoeinCancer Science Institute of Singapore, Singapore, Singapore.ORCID http://orcid.org/0000-0002-6019-9504
S UmmarinoHarvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA.
M T N LeDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
J G DoenchGenetic Perturbation Platform, Broad Institute, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3707-9889
T BenoukrafCancer Science Institute of Singapore, Singapore, Singapore.ORCID http://orcid.org/0000-0002-4789-8028
L ChaiDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1937-4750
D HiwaseRoyal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0002-6666-3056
D ThomasRoyal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0002-0837-1231
A Di RuscioDepartment of Translational Medicine, University of Eastern Piedmont, Novara, Italy.ORCID http://orcid.org/0000-0002-9705-4245
D G TenenHarvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA. dtenen@bidmc.harvard.edu.ORCID http://orcid.org/0000-0002-6423-3888
M A BassalHarvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA. mahmoud.bassal@mymail.unisa.edu.au.ORCID http://orcid.org/0000-0003-4322-2968

Funding

Transcriptional and epigenetic heterogeneity of stem/progenitor cellsP01HL131477 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Jason Daniel Buenrostro · 2017 to 2026
$24.6M
Novel Strategies to Improve Blood Transfusion PracticeP01HL158688 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Hongbo R Luo · 2022 to 2026
$12.9M
Mechanisms of regulation by RNA in acute myeloid leukemiaR35CA197697 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI TENEN, DANIEL G · 2015 to 2021
$7.1M
Understanding the role of cell-cycle specific RNAs in hematopoiesisR01DK136116 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Annalisa Di Ruscio · 2022 to 2026
$1.7M
Determining the role of DNMT-interacting RNAs in myeloid disordersR00CA188595 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI DI RUSCIO, ANNALISA · 2017 to 2019
$747k
Fondazione Cariplo (Cariplo Foundation) 2016-0476NCI NIH HHS R00 CA188595NCI NIH HHS R35 CA197697NHLBI NIH HHS P01 HL131477NHLBI NIH HHS P01 HL158688NIDDK NIH HHS R01 DK136116U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) P01HL158688
6 · The paper itself

Abstract

DNA methylation regulates transcription, yet the demethylation of canonical elements like promoter CpG islands exhibits inconsistent correlations with gene activation. We hypothesize that causal regulatory elements are defined by biophysical hypersensitivity. Profiling 24 whole-genome bisulfite sequencing samples across diverse human and murine models, we identify Methylation Mesa, narrow (~45-300 bp), structurally conserved epigenetic regulatory elements. Mesa show enrichment in 5' untranslated regions and associate with transcriptional activation significantly better than canonical promoters. To investigate causal regulatory dynamics, we develop CRISPR-DiR, an RNA-based targeted demethylation technology offering greater spatial precision, higher potency, and reduced toxicity compared to CRISPR-TET1. While proximal promoter demethylation initiated limited early transcription, focal demethylation of the Mesa seed acts as the primary driver of exponential CDKN2A (p16) reactivation and robust in vivo tumor suppression. We demonstrate that precise demethylation of a Mesa locus triggers localized demethylation, subsequent activation histone mark deposition, and long-range three-dimensional chromatin rewiring. Thus, Methylation Mesa act as precise, dominant epigenetic regulatory hubs, and CRISPR-DiR as a potent high-resolution tool, establishing a structural framework for biomarker discovery and targeted therapies.

Indexed as

DNA MethylationRegulatory Sequences, Nucleic AcidTranscriptional Activation5' Untranslated RegionsAnimalsChromatinCpG IslandsCRISPR-Cas SystemsEpigenesis, GeneticEpigenome EditingHumansMicePromoter Regions, Genetic5' Untranslated RegionsChromatin

Identifiers

PMID42786170
PMCPMC13612829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.